CN110973634A - 改善发育迟缓的营养组合物及其制备方法 - Google Patents
改善发育迟缓的营养组合物及其制备方法 Download PDFInfo
- Publication number
- CN110973634A CN110973634A CN201911354955.6A CN201911354955A CN110973634A CN 110973634 A CN110973634 A CN 110973634A CN 201911354955 A CN201911354955 A CN 201911354955A CN 110973634 A CN110973634 A CN 110973634A
- Authority
- CN
- China
- Prior art keywords
- parts
- oil microcapsule
- microcapsule powder
- amount
- premix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000000843 powder Substances 0.000 claims abstract description 96
- 239000003094 microcapsule Substances 0.000 claims abstract description 68
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 38
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims abstract description 38
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 38
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 30
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 23
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 22
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 21
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 21
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 19
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 19
- 235000010216 calcium carbonate Nutrition 0.000 claims abstract description 19
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 19
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 19
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 19
- 235000019172 retinyl palmitate Nutrition 0.000 claims abstract description 19
- 239000011769 retinyl palmitate Substances 0.000 claims abstract description 19
- 229940108325 retinyl palmitate Drugs 0.000 claims abstract description 19
- 229960003080 taurine Drugs 0.000 claims abstract description 19
- 229960000984 tocofersolan Drugs 0.000 claims abstract description 19
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 19
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 19
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 19
- 239000002076 α-tocopherol Substances 0.000 claims abstract description 19
- 235000004835 α-tocopherol Nutrition 0.000 claims abstract description 19
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 19
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 17
- 239000004222 ferrous gluconate Substances 0.000 claims abstract description 17
- 229960001645 ferrous gluconate Drugs 0.000 claims abstract description 17
- 235000013924 ferrous gluconate Nutrition 0.000 claims abstract description 17
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims abstract description 17
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 17
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 15
- 239000011578 levomefolic acid Substances 0.000 claims abstract description 15
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 15
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 15
- 229940088594 vitamin Drugs 0.000 claims abstract description 15
- 229930003231 vitamin Natural products 0.000 claims abstract description 15
- 235000013343 vitamin Nutrition 0.000 claims abstract description 15
- 239000011782 vitamin Substances 0.000 claims abstract description 15
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 14
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 14
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 14
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 14
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims abstract description 13
- 235000007635 levomefolic acid Nutrition 0.000 claims abstract description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 10
- 241000196324 Embryophyta Species 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 9
- 239000010775 animal oil Substances 0.000 claims abstract description 9
- 239000008158 vegetable oil Substances 0.000 claims abstract description 6
- 235000015097 nutrients Nutrition 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 37
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 26
- 238000001291 vacuum drying Methods 0.000 claims description 17
- 235000019498 Walnut oil Nutrition 0.000 claims description 16
- 235000021388 linseed oil Nutrition 0.000 claims description 16
- 239000000944 linseed oil Substances 0.000 claims description 16
- 239000008170 walnut oil Substances 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 14
- 239000003921 oil Substances 0.000 claims description 14
- 235000019198 oils Nutrition 0.000 claims description 14
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 14
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 13
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 13
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 13
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 13
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 13
- 229960002477 riboflavin Drugs 0.000 claims description 13
- 235000019192 riboflavin Nutrition 0.000 claims description 13
- 239000002151 riboflavin Substances 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 13
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 13
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 13
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 13
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 11
- 206010012559 Developmental delay Diseases 0.000 claims description 9
- 229960003563 calcium carbonate Drugs 0.000 claims description 9
- 229960001708 magnesium carbonate Drugs 0.000 claims description 9
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 241000195493 Cryptophyta Species 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- JMNIIIQOMSQWJN-ZEXVLMPOSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-ZEXVLMPOSA-L 0.000 claims description 3
- 239000010773 plant oil Substances 0.000 claims description 3
- FZDRYCKUVGVDSO-KWWXADPNSA-N (2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid;(2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal Chemical class O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO.C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FZDRYCKUVGVDSO-KWWXADPNSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 3
- 239000003623 enhancer Substances 0.000 description 31
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 26
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 22
- 238000011161 development Methods 0.000 description 21
- 230000018109 developmental process Effects 0.000 description 20
- 239000002994 raw material Substances 0.000 description 18
- 230000012010 growth Effects 0.000 description 16
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 12
- 229960005070 ascorbic acid Drugs 0.000 description 12
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 12
- 210000003754 fetus Anatomy 0.000 description 12
- 239000008107 starch Substances 0.000 description 12
- 235000019698 starch Nutrition 0.000 description 12
- 239000002211 L-ascorbic acid Substances 0.000 description 11
- 235000000069 L-ascorbic acid Nutrition 0.000 description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- -1 (6S) -5-methyltetrahydrofolic acid glucosamine salt Chemical class 0.000 description 8
- 210000004958 brain cell Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229930003316 Vitamin D Natural products 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 235000019166 vitamin D Nutrition 0.000 description 7
- 239000011710 vitamin D Substances 0.000 description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 description 7
- 229940046008 vitamin d Drugs 0.000 description 7
- 208000030941 fetal growth restriction Diseases 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 6
- 239000011724 folic acid Substances 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 208000032170 Congenital Abnormalities Diseases 0.000 description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960000304 folic acid Drugs 0.000 description 5
- 208000037824 growth disorder Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010070531 Foetal growth restriction Diseases 0.000 description 3
- 206010016880 Folate deficiency Diseases 0.000 description 3
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 206010009260 Cleft lip and palate Diseases 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- 208000034423 Delivery Diseases 0.000 description 2
- 206010070538 Gestational hypertension Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 201000005624 HELLP Syndrome Diseases 0.000 description 2
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000016653 cleft lip/palate Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010060919 Foetal malformation Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 1
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 1
- 208000001184 Oligohydramnios Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000036995 brain health Effects 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 231100000020 developmental retardation Toxicity 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009593 intrauterine fetal growth Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 230000024764 neural tube development Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于营养食品技术领域，具体涉及改善发育迟缓的营养组合物，按重量份计包括如下组分：30‑80份含α‑亚麻酸的植物种子油微囊粉、20‑100份含DHA的动植物油微囊粉、0.001‑0.008份磷脂酰丝氨酸、0.001‑0.005份(6S)‑5‑甲基四氢叶酸盐、1‑5份维生素组合物预混料、5‑35份碳酸钙，0.2‑25份碳酸镁、0.5‑6份葡萄糖酸亚铁、0.1‑3份葡萄糖酸锌，0.01‑0.1份棕榈酸视黄酯、0.01‑0.05份维生素D3、0.1‑2份d‑α‑生育酚、0.1‑5份牛磺酸、5‑25份大豆分离蛋白粉。本发明还提供了上述组合物的制备方法。本发明营养物质全面，吸收率高，并且可以结合传统物理治疗的方法，食用方便，效果显著，无任何明显副作用。
Description
技术领域
本发明属于营养食品技术领域，具体涉及改善发育迟缓的营养组合物及其制备方法。
背景技术
生长发育迟缓(发育迟缓)是指在生长发育过程中出现速度放慢或是顺序异常等现象。发病率在6％～8％之间。发育迟缓的诱因很多，例如营养不足、全身疾病、家族遗传、先天性疾病或精神因素。胎儿宫内发育迟缓(fetal growth restriction,FGR)是一种严重危害胎儿生存质量并影响儿童期及***生长发育、甚至可导致多种远期并发症的产科疾患，有发育迟缓的儿童80％到90％的患者中有宫内发育不良以及先天性遗传的因素导致。还有一些是因为病理因素导致孩子的生长迟缓，例如是一些染色体的异常，骨骼疾病，代谢性的疾病，慢性疾病或者是慢性营养不良，以及内分泌的一些疾病等，这些疾病都会引发孩子出现生长发育迟缓的情况。孕妇是胎儿营养物质的基本来源，孕妇营养不良，尤其是蛋白质和能量供应不足即会影响胎儿的生长发育。另外，人体必需的微量元素与氨基酸、蛋白质等结合可形成具有高度生化效应和特殊生理功能的酶和激素，微量元素和维生素的缺乏可影响胎儿的生长发育。如孕妇缺锌可影响核酸和蛋白质的合成，胎盘绒毛总面积缩小，影响胎儿发育，可导致IUGR和胎儿畸形。由于酶的缺陷或维生素B6、B12或叶酸供应不足可造成高高半胱氨酸血症，影响胎儿胎盘发育，可引发流产、妊高征、IUGR、畸胎和胎盘早剥等产科并发症。本发明公布了一种对胎儿宫内发育迟缓及幼儿生长发育迟缓均有显著作用的营养组合物，是从营养吸收与代谢角度提供的一种新方法，既对胎儿宫内发育迟缓有改善效果，亦对儿童成长发育迟缓有改善效果。
α-亚麻酸是人体必需脂肪酸，在人体内可转化为二十碳五烯酸和二十二碳六烯酸，α-亚麻酸可增加脑部传递介质(Neurotransmitter)，加强脑部活动功能，令脑部运作更有效，学习思考能力更佳。α-亚麻酸对孕产妇最重要的作用是：控制基因表达、优化遗传基因、转运细胞物质原料、控制养分进入细胞，影响胎婴儿脑细胞的生长发育。α-亚麻酸亦是脑黄金DHA，可在婴儿体内分别转化为DHA；α-亚麻酸对胎儿和婴儿的脑部、视网膜、皮肤和肾功能的健康发育十分重要。
DHA是大脑细胞膜的重要构成成分，参与脑细胞的形成和发育，对神经细胞轴突的延伸和新突起的形成有重要作用，可维持神经细胞的正常生理活动，参与大脑思维和记忆形成过程。可能与促进神经细胞蛋白质合成有关,促进神经细胞的生长。DHA和脑健康的关系非常密切。增加食物中DHA的含量，有助于脑中DHA水平的提高，从而有利于增强学习记忆功能，有利于脑和神经的健康发育,有利于防治视力下降。
磷脂酰丝氨酸它构成神经细胞的细胞膜，活化蛋白激酶C(protein kinase，PKC)，而激活的蛋白激酶C可以使丝氨酸和苏氨酸残基磷酸化，从而影响生物信息传导，可帮助修复尤其针对脑神经细胞膜，磷脂酰丝氨酸不但将营养素带入细胞、排出废物，更可以帮助脑细胞正常化。磷脂酰丝氨酸可帮助修复尤其针对脑神经细胞膜，磷脂酰丝氨酸不但将营养素带入细胞、排出废物，更可以帮助脑细胞正常化。
叶酸是维持人体正常生命活动必需的一种水溶性B族维生素，其主要生物学功能是为细胞内的甲基化反应和脱氧核糖核酸的合成提供甲基。研究表明，以神经管畸形、唇腭裂等多种出生缺陷与女性孕早期体内缺乏叶酸有关，叶酸是胎儿生长发育不可缺少的营养素，孕妇缺乏叶酸有可能导致胎儿出生时出现低体重、唇腭裂、心脏缺陷等，如果在怀孕头3个月内缺乏叶酸，可引起胎儿神经管发育缺陷，而导致畸形。与叶酸相反，(6S)-5-甲基四氢叶酸，氨基葡萄糖盐作为一种有代谢活性的叶酸盐，它不受MTHFR酶(亚甲基四氢叶酸还原酶)基因多态性的影响，可以直接利用而不需要任何代谢的“成品”叶酸，摄入5-甲基四氢叶酸以确保Hcy能完成蛋氨酸循环，降低血液中的Hcy含量，避免孕早期Hcy升高引起的自然性流产，胎停育，出生缺陷等；缓解孕中晚期Hcy升高引起的胎盘三级绒毛膜小血管的闭塞和血管硬化甚至胎儿循环***血栓形成，进而造成羊水过少，胎儿生长发育受限，妊高症，早产等不良后果。
维生素E可以增强宝宝脑神经细胞的活力，维持宝宝正常的免疫功能，特别是对T淋巴细胞的功能。保护神经***、骨髓肌、视网膜免受氧化损伤的作用。人体神经肌肉***的正常发育和视网膜的功能维持也需要足够的维生素E。钙是保持心脏健康、止血、神经健康、肌肉收缩以及皮肤、骨骼和牙齿健康的营养素。锌是体内200多种酶以及DNA、RNA的组成成分，是生长发育的必需物质。
维生素D能促进小肠黏膜对钙和磷的吸收，有效促骨的破骨细胞、新骨细胞生长，维持钙的浓度，促进钙在骨里面沉着，让骨头硬化。而且维生素D还参与多种细胞的增殖、分化，调节免疫功能。
多种维生素矿物质是维持机体生命不可缺少的重要物质，维生素参与机体许多重要的生命过程，与人体的健康关系甚大，因为婴幼儿正处于生长发育旺盛时期，对各种维生素需要量较大，应当注意补充。矿物质又称无机盐，在人体内矿物质虽然含量很少，但有的矿物质是构成机体组织必需的原料，有的与维持酶和激素活性有关。因此在婴幼儿生长发育处于旺盛时期摄入足够的矿物质更为重要。怀孕期母体对营养的需求增加，这是因为胎儿血液循环、胎儿器官和骨骼生子发育、胎盘生长等需要更多的营养，以及母体本身重要器官工作量增加等所致。所以在怀孕时期，应摄入足够的多种维生素矿物质，避免饮食中的营养缺乏，保证身体处于最佳状态，使自己血液中能含有足够的、为胎儿所需的一切营养物质。
牛磺酸是神经抑制因子，可促进神经***生长发育，神经细胞增殖分化，缺乏者可使发育中的小脑发育异常，影响大脑和智力发育。另外还可促进脑细胞DNA、RNA的合成，增加膜的磷脂酰乙醇胺含量和脑细胞对蛋白质的利用率，从而促进脑细胞尤其是海马细胞结构和功能的发育。现市面上尚无全面针对性的营养组合物，针对改善发育迟缓的营养制剂成分单一，主要为药物制剂以配合物理治疗，并且单一成分易造成吸收不佳，因此治疗效果不理想。
发明内容
本发明目的是为了解决上述问题，提供了从胚胎发育期母体及生长发育期儿童的营养吸收及营养代谢角度全面针对性的改善发育迟缓的营养组合物，以及改善发育迟缓的营养组合物的制备方法。
本发明提供了改善发育迟缓的营养组合物，具体技术方案如下：
改善发育迟缓的营养组合物，按重量份计包括如下组分：30-80份含α-亚麻酸的植物种子油微囊粉、20-100份含DHA的动植物油微囊粉、0.001-0.008份磷脂酰丝氨酸、0.001-0.005份(6S)-5-甲基四氢叶酸盐、1-5份维生素组合物预混料、5-35份碳酸钙，0.2-25份碳酸镁、0.5-6份葡萄糖酸亚铁、0.1-3份葡萄糖酸锌，0.01-0.1份棕榈酸视黄酯、0.01-0.05份维生素D3、0.1-2份d-α-生育酚、0.1-5份牛磺酸、5-25份大豆分离蛋白粉。
在某些实施方式中，所述含α-亚麻酸的植物种子油微囊粉包括亚麻籽油微囊粉和核桃油微囊粉，所述亚麻籽油微囊粉与所述核桃油微囊粉重量份比例为2:3-5:1。
在某些实施方式中，所述含DHA的动植物油微囊粉为DHA藻油微囊粉、鱼油微囊粉和/或卵磷脂DHA蛋黄微囊粉。
在某些实施方式中，所述维生素组合物预混料为复配营养素强化剂预混料，每1000份所述的复配营养素强化剂预混料中含10-15份盐酸硫胺素、10-15份核黄素、10-15份盐酸吡哆醇、1-5份钴胺素、65-80份烟酰胺、740-753份L-抗坏血酸、47-55份D-泛酸钙，余量为淀粉。
在某些实施方式中，所述(6S)-5-甲基四氢叶酸盐为(6S)-5-甲基四氢叶酸氨基葡萄糖盐或(6S)-5-甲基四氢叶酸钙和(6S)-5-甲基四氢叶酸组合物。
在某些实施方式中，亚麻籽油微囊粉为30份、核桃油微囊粉为20份、DHA藻油微囊粉为20份、磷脂酰丝氨酸为0.005份、(6S)-5-甲基四氢叶酸氨基葡萄糖盐为0.003份、复配营养素强化剂预混料为3份、碳酸钙为5份、碳酸镁为2份、葡萄糖酸亚铁为1份、葡萄糖酸锌为0.1份、棕榈酸视黄酯为0.01份、维生素D3为0.02份、d-α-生育酚为0.2份。
本发明还提供了改善发育迟缓的营养组合物的制备方法，用于制备上述营养组合物的制备方法，其特征在于，包括如下步骤：
(1)将含α-亚麻酸的植物种子油微囊粉、含DHA的动植物油微囊粉、磷脂酰丝氨酸、份(6S)-5-甲基四氢叶酸盐、维生素组合物预混料、碳酸钙、碳酸镁、葡萄糖酸亚铁、葡萄糖酸锌、棕榈酸视黄酯、维生素D3、d-α-生育酚、牛磺酸、大豆分离蛋白粉分别进行过筛；
(2)将过筛后的磷脂酰丝氨酸、(6S)-5-甲基四氢叶酸盐、维生素组合物预混料、碳酸钙、碳酸镁、葡萄糖酸亚铁、葡萄糖酸锌、棕榈酸视黄酯、维生素D3、d-α-生育酚、牛磺酸置于粉末混合机中混合均匀，获得混合物A；
(3)将过筛后的含α-亚麻酸的植物种子油微囊粉、含DHA的动植物油微囊粉、大豆分离蛋白粉和步骤(2)中的混合物A置于真空干燥混合机中混合均匀，获得改善发育迟缓的营养组合物；
(4)将步骤(3)中的改善发育迟缓的营养组合物制成粉剂、片剂或胶囊。
本发明具有以下有益效果：本发明的改善发育迟缓的营养组合物含α-亚麻酸、DHA、(6S)-5-甲基四氢叶酸和多种维生素矿物质等丰富的营养物质，这些营养物质之间可以相互促进吸收，从而增强吸收率，并且可以结合传统物理治疗的方法，食用方便，效果显著，无任何明显副作用。
附图说明
图1是本发明的改善发育迟缓的营养组合物的制备方法的流程图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明白，以下结合具体实施例，并参照附图1，对本发明进一步详细说明。
实施例1
按重量份称取：亚麻籽油微囊粉20份、核桃油微囊粉25份、DHA藻油微囊粉100份、磷脂酰丝氨酸0.001份、(6S)-5-甲基四氢叶酸氨基葡萄糖盐0.005份、复配营养素强化剂预混料5份、碳酸钙35份，碳酸镁0.2份、葡萄糖酸亚铁0.5份、葡萄糖酸锌3份、棕榈酸视黄酯0.1份、维生素D3 0.05份、d-α-生育酚2份、牛磺酸0.1份、大豆分离蛋白5份。其中，复配营养素强化剂预混料的配制如下：每1000份预混料中含盐酸硫胺素13份、核黄素13份、盐酸吡哆醇12份、钴胺素3份、烟酰胺70份、L-抗坏血酸745份、D-泛酸钙50份，余量为淀粉，将上述原料处理后在真空干燥混合机忠混合均匀，制成片剂、粉剂或胶囊剂的复配营养素强化剂预混料。
将上述所称取的材料分别过60目筛，按配方量将磷脂酰丝氨酸、(6S)-5-甲基四氢叶酸氨基葡萄糖盐、复配营养素强化剂预混料、碳酸钙、碳酸镁、葡萄糖酸亚铁、葡萄糖酸锌、棕榈酸视黄酯、维生素D3、d-α-生育酚、牛磺酸经粉末混合机混合30min，制得混合物A，将亚麻籽油微囊粉、核桃油微囊粉、DHA藻油微囊粉、大豆分离蛋白粉及混合物A经真空干燥混合机均匀混合20-40min，制成粉剂的改善发育迟缓的营养组合物。
实施例2
复配营养素强化剂预混料的配制如下：每1000份预混料中含盐酸硫胺素10份、核黄素10份、盐酸吡哆醇10份、钴胺素1份、烟酰胺65份、L-抗坏血酸740份、D-泛酸钙47份，余量为淀粉，将上述原料处理后在真空干燥混合机忠混合均匀，制成片剂、粉剂或胶囊剂的复配营养素强化剂预混料。
其余制备改善发育迟缓的营养组合物的原料的重量份以及制备方法与实施例1相同。
实施例3
复配营养素强化剂预混料的配制如下：每1000份预混料中含盐酸硫胺素15份、核黄素15份、盐酸吡哆醇15份、钴胺素5份、烟酰胺80份、L-抗坏血酸753份、D-泛酸钙55份，余量为淀粉，将上述原料处理后在真空干燥混合机忠混合均匀，制成片剂、粉剂或胶囊剂的复配营养素强化剂预混料。
其余制备改善发育迟缓的营养组合物的原料的重量份以及制备方法与实施例1相同。
实施例4
按重量份称取：亚麻籽油微囊粉50份、核桃油微囊粉30份、DHA藻油微囊粉45份、磷脂酰丝氨酸0.001份、(6S)-5-甲基四氢叶酸氨基葡萄糖盐0.008份、复配营养素强化剂预混料1份、碳酸钙5份，碳酸镁25份、葡萄糖酸亚6份、葡萄糖酸锌0.1份、棕榈酸视黄酯0.1份、维生素D3 0.01份、d-α-生育酚0.03份、牛磺酸5份、大豆分离蛋白25份。其中，复配营养素强化剂预混料的配制如下：每1000份预混料中含盐酸硫胺素13份、核黄素13份、盐酸吡哆醇12份、钴胺素3份、烟酰胺70份、L-抗坏血酸745份、D-泛酸钙50份，余量为淀粉，将上述原料处理后在真空干燥混合机忠混合均匀，制成片剂、粉剂或胶囊剂的复配营养素强化剂预混料。
将上述所称取的材料分别过60目筛，按配方量将磷脂酰丝氨酸、(6S)-5-甲基四氢叶酸氨基葡萄糖盐、复配营养素强化剂预混料、碳酸钙、碳酸镁、葡萄糖酸亚铁、葡萄糖酸锌、棕榈酸视黄酯、维生素D3、d-α-生育酚、牛磺酸经粉末混合机混合30min，制得混合物A，将亚麻籽油微囊粉、核桃油微囊粉、DHA藻油微囊粉、大豆分离蛋白粉及混合物A经真空干燥混合机均匀混合20-40min，制成胶囊剂的改善发育迟缓的营养组合物。
实施例5
复配营养素强化剂预混料的配制如下：每1000份预混料中含盐酸硫胺素10份、核黄素10份、盐酸吡哆醇10份、钴胺素1份、烟酰胺65份、L-抗坏血酸740份、D-泛酸钙47份，余量为淀粉，将上述原料处理后在真空干燥混合机忠混合均匀，制成片剂、粉剂或胶囊剂的复配营养素强化剂预混料。
其余制备改善发育迟缓的营养组合物的原料的重量份以及制备方法与实施例4相同。
实施例6
复配营养素强化剂预混料的配制如下：每1000份预混料中含盐酸硫胺素15份、核黄素15份、盐酸吡哆醇15份、钴胺素5份、烟酰胺80份、L-抗坏血酸753份、D-泛酸钙55份，余量为淀粉，将上述原料处理后在真空干燥混合机忠混合均匀，制成片剂、粉剂或胶囊剂的复配营养素强化剂预混料。
其余制备改善发育迟缓的营养组合物的原料的重量份以及制备方法与实施例4相同。
实施例7
按重量份称取：亚麻籽油微囊粉30份、核桃油微囊粉20份、DHA藻油微囊粉20份、磷脂酰丝氨酸0.005份、(6S)-5-甲基四氢叶酸氨基葡萄糖盐0.003份、复配营养素强化剂预混料3份、碳酸钙5份，碳酸镁2份、葡萄糖酸亚1份、葡萄糖酸锌0.1份、棕榈酸视黄酯0.1份、维生素D3 0.02份、d-α-生育酚0.02份、牛磺酸2份、大豆分离蛋白15份。其中，复配营养素强化剂预混料的配制如下：每1000份预混料中含盐酸硫胺素13份、核黄素13份、盐酸吡哆醇12份、钴胺素3份、烟酰胺70份、L-抗坏血酸745份、D-泛酸钙50份，余量为淀粉，将上述原料处理后在真空干燥混合机忠混合均匀，制成片剂、粉剂或胶囊剂的复配营养素强化剂预混料。
将上述所称取的材料分别过60目筛，按配方量将磷脂酰丝氨酸、(6S)-5-甲基四氢叶酸氨基葡萄糖盐、复配营养素强化剂预混料、碳酸钙、碳酸镁、葡萄糖酸亚铁、葡萄糖酸锌、棕榈酸视黄酯、维生素D3、d-α-生育酚、牛磺酸经粉末混合机混合30min，制得混合物A，将亚麻籽油微囊粉、核桃油微囊粉、DHA藻油微囊粉、大豆分离蛋白粉及混合物A经真空干燥混合机均匀混合20-40min，制成片剂的改善发育迟缓的营养组合物。
实施例8
复配营养素强化剂预混料的配制如下：每1000份预混料中含盐酸硫胺素10份、核黄素10份、盐酸吡哆醇10份、钴胺素1份、烟酰胺65份、L-抗坏血酸740份、D-泛酸钙47份，余量为淀粉，将上述原料处理后在真空干燥混合机忠混合均匀，制成片剂、粉剂或胶囊剂的复配营养素强化剂预混料。
其余制备改善发育迟缓的营养组合物的原料的重量份以及制备方法与实施例7相同。
实施例9
复配营养素强化剂预混料的配制如下：每1000份预混料中含盐酸硫胺素15份、核黄素15份、盐酸吡哆醇15份、钴胺素5份、烟酰胺80份、L-抗坏血酸753份、D-泛酸钙55份，余量为淀粉，将上述原料处理后在真空干燥混合机忠混合均匀，制成片剂、粉剂或胶囊剂的复配营养素强化剂预混料。
其余制备改善发育迟缓的营养组合物的原料的重量份以及制备方法与实施例7相同。
实施例10
按重量份称取：亚麻籽油微囊粉45份、核桃油微囊粉10份、DHA藻油微囊粉20份、磷脂酰丝氨酸0.005份、(6S)-5-甲基四氢叶酸氨基葡萄糖盐0.045份、复配营养素强化剂预混料3份、碳酸钙7份，碳酸镁2份、葡萄糖酸亚铁1份、葡萄糖酸锌0.3份、棕榈酸视黄酯0.01份、维生素D3 0.01份、d-α-生育酚0.1份、牛磺酸0.2份、大豆分离蛋白15份。其中，复配营养素强化剂预混料的配制如下：每1000份预混料中含盐酸硫胺素10-14份、核黄素10-15份、盐酸吡哆醇10-15份、钴胺素1-5份、烟酰胺65-80份、L-抗坏血酸740-753份、D-泛酸钙47-55份，余量为淀粉，将上述原料处理后在真空干燥混合机忠混合均匀，制成片剂、粉剂或胶囊剂的复配营养素强化剂预混料。
将上述所称取的材料分别过60目筛，按配方量将磷脂酰丝氨酸、(6S)-5-甲基四氢叶酸氨基葡萄糖盐、复配营养素强化剂预混料、碳酸钙、碳酸镁、葡萄糖酸亚铁、葡萄糖酸锌、棕榈酸视黄酯、维生素D3、d-α-生育酚、牛磺酸经粉末混合机混合30min，制得混合物A，将亚麻籽油微囊粉、核桃油微囊粉、DHA藻油微囊粉、大豆分离蛋白及混合物A经真空干燥混合机均匀混合20-40min，制成粉剂的改善发育迟缓的营养组合物，每袋20克，每日服用90克。
通过选取8市在产科收治胎儿宫内发育迟缓孕妇48例，孕妇年龄24～42岁，平均29岁；孕25周～35周结果48例孕妇中经***分娩28例，剖宫产20例，新生儿均存活。新生儿体重≥2500g 40例，新生儿体重≥3000g 5例，其中3例孕妇分娩周数为34～36周，新生儿体重≥2200g。效果具有显著性。
实施例11
按重量份称取：亚麻籽油微囊粉20份、核桃油微囊粉10份、DHA藻油微囊粉45份、磷脂酰丝氨酸0.006份、(6S)-5-甲基四氢叶酸钙0.004份、复配营养素强化剂预混料2份、碳酸钙12份、碳酸镁2份、葡萄糖酸亚铁3份、葡萄糖酸锌0.9份、棕榈酸视黄酯0.06份、维生素D30.02份、d-α-生育酚0.03份、牛磺酸0.25份、大豆分离蛋白12份。
其中，复配营养素强化剂预混料的配制如下：每1000份预混料中含盐酸硫胺素13份，核黄素13份、盐酸吡哆醇12份、钴胺素3份、烟酰胺75份、L-抗坏血酸745份、D-泛酸钙50份，余量为淀粉，将上述原料处理后在真空干燥混合机忠混合均匀，制成片剂、粉剂或胶囊剂的复配营养素强化剂预混料。
将上述原料分别过60目筛，按配方量将磷脂酰丝氨酸、(6S)-5-甲基四氢叶酸钙、复配营养素强化剂预混料、碳酸钙、碳酸镁、葡萄糖酸亚铁、葡萄糖酸锌、棕榈酸视黄酯、维生素D3、d-α-生育酚、牛磺酸经粉末混合机混合30min，制得混合物A，将亚麻籽油微囊粉、核桃油微囊粉、DHA藻油微囊粉、大豆分离蛋白及混合物A经真空干燥混合机均匀混合20-40min，制成粉剂的改善发育迟缓的营养组合物，每袋20克，每日服用60克。
选取身材矮小、语言和运动能力均与同龄儿童有差距的20个月至5周岁儿童298人，均在儿童医院确诊为发育迟缓的患儿，服用6个月到12个月后，260名患儿的体格发育指标、语言和运动能力评价指标均接近同龄人水平或与同龄人水平无异。
上述仅本发明较佳可行实施例，并非是对本发明的限制，本发明也并不限于上述举例，本技术领域的技术人员，在本发明的实质范围内，所作出的变化、改型、添加或替换，也应属于本发明的保护范围。
Claims (7)
1.改善发育迟缓的营养组合物，其特征在于，按重量份计包括如下组分：30-80份含α-亚麻酸的植物种子油微囊粉、20-100份含DHA的动植物油微囊粉、0.001-0.008份磷脂酰丝氨酸、0.001-0.005份(6S)-5-甲基四氢叶酸盐、1-5份维生素组合物预混料、5-35份碳酸钙，0.2-25份碳酸镁、0.5-6份葡萄糖酸亚铁、0.1-3份葡萄糖酸锌，0.01-0.1份棕榈酸视黄酯、0.01-0.05份维生素D3、0.1-2份d-α-生育酚、0.1-5份牛磺酸、5-25份大豆分离蛋白粉。
2.根据权利要求1所述的改善发育迟缓的营养组合物，其特征在于，所述含α-亚麻酸的植物种子油微囊粉包括亚麻籽油微囊粉和核桃油微囊粉，所述亚麻籽油微囊粉与所述核桃油微囊粉重量份比例为2:3-5:1。
3.根据权利要求2所述的改善发育迟缓的营养组合物，其特征在于，所述含DHA的动植物油微囊粉为DHA藻油微囊粉、鱼油微囊粉和/或卵磷脂DHA蛋黄微囊粉。
4.根据权利要求3所述的改善发育迟缓的营养组合物，其特征在于，所述维生素组合物预混料为复配营养素强化剂预混料，每1000份所述的复配营养素强化剂预混料中含10-15份盐酸硫胺素、10-15份核黄素、10-15份盐酸吡哆醇、1-5份钴胺素、65-80份烟酰胺、740-753份L-抗坏血酸、47-55份D-泛酸钙，余量为淀粉。
5.根据权利要求1所述的改善发育迟缓的营养组合物，其特征在于，所述(6S)-5-甲基四氢叶酸盐为(6S)-5-甲基四氢叶酸氨基葡萄糖盐或(6S)-5-甲基四氢叶酸钙和(6S)-5-甲基四氢叶酸混合物。
6.根据权利要求4所述的改善发育迟缓的营养组合物，其特征在于，亚麻籽油微囊粉为30份、核桃油微囊粉为20份、DHA藻油微囊粉为20份、磷脂酰丝氨酸为0.005份、(6S)-5-甲基四氢叶酸氨基葡萄糖盐为0.003份、复配营养素强化剂预混料为3份、碳酸钙为5份、碳酸镁为2份、葡萄糖酸亚铁为1份、葡萄糖酸锌为0.1份、棕榈酸视黄酯为0.01份、维生素D3为0.02份、d-α-生育酚为0.2份。
7.改善发育迟缓的营养组合物的制备方法，用于制备权利要求1-6任一项所述的营养组合物的制备方法，其特征在于，包括如下步骤：
(1)将含α-亚麻酸的植物种子油微囊粉、含DHA的动植物油微囊粉、磷脂酰丝氨酸、份(6S)-5-甲基四氢叶酸盐、维生素组合物预混料、碳酸钙、碳酸镁、葡萄糖酸亚铁、葡萄糖酸锌、棕榈酸视黄酯、维生素D3、d-α-生育酚、牛磺酸、大豆分离蛋白粉分别进行过筛；
(2)将过筛后的磷脂酰丝氨酸、(6S)-5-甲基四氢叶酸盐、维生素组合物预混料、碳酸钙、碳酸镁、葡萄糖酸亚铁、葡萄糖酸锌、棕榈酸视黄酯、维生素D3、d-α-生育酚、牛磺酸置于粉末混合机中混合均匀，获得混合物A；
(3)将过筛后的含α-亚麻酸的植物种子油微囊粉、含DHA的动植物油微囊粉、大豆分离蛋白粉和步骤(2)中的混合物A置于真空干燥混合机中混合均匀，获得改善发育迟缓的营养组合物；
(4)将步骤(3)中的改善发育迟缓的营养组合物制成粉剂、片剂或胶囊。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911354955.6A CN110973634A (zh) | 2019-12-25 | 2019-12-25 | 改善发育迟缓的营养组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911354955.6A CN110973634A (zh) | 2019-12-25 | 2019-12-25 | 改善发育迟缓的营养组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110973634A true CN110973634A (zh) | 2020-04-10 |
Family
ID=70075288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911354955.6A Pending CN110973634A (zh) | 2019-12-25 | 2019-12-25 | 改善发育迟缓的营养组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110973634A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060217386A1 (en) * | 2005-03-10 | 2006-09-28 | Edwards John B | Nutritional preparations |
| CN102458150A (zh) * | 2009-06-02 | 2012-05-16 | 雀巢产品技术援助有限公司 | 支持幼儿脑发育和功能的营养组合物 |
| CN107348480A (zh) * | 2017-05-19 | 2017-11-17 | 云南雪域印象生物科技有限公司 | 核桃油微胶囊蛋白粉 |
| CN108477622A (zh) * | 2018-04-16 | 2018-09-04 | 赵成群 | 一种婴幼儿全功能营养组合物 |
-
2019
- 2019-12-25 CN CN201911354955.6A patent/CN110973634A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060217386A1 (en) * | 2005-03-10 | 2006-09-28 | Edwards John B | Nutritional preparations |
| CN102458150A (zh) * | 2009-06-02 | 2012-05-16 | 雀巢产品技术援助有限公司 | 支持幼儿脑发育和功能的营养组合物 |
| CN107348480A (zh) * | 2017-05-19 | 2017-11-17 | 云南雪域印象生物科技有限公司 | 核桃油微胶囊蛋白粉 |
| CN108477622A (zh) * | 2018-04-16 | 2018-09-04 | 赵成群 | 一种婴幼儿全功能营养组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krishnaswamy et al. | Importance of folate in human nutrition | |
| US7674490B2 (en) | Food and vitamin preparations containing the natural isomer of reduced folates | |
| MX2007011046A (es) | Preparaciones nutritivas. | |
| CN104382934A (zh) | 一种孕妇多维片 | |
| CN105962379B (zh) | 一种b族维生素片及其制备方法 | |
| CN106689698B (zh) | 一种奶牛产后灌服营养补充剂及其生产方法 | |
| CN107467667B (zh) | 一种含有两种不饱和脂肪酸和唾液酸的复方制剂 | |
| CN101176734A (zh) | 一种用于补充叶酸及维生素b12的营养素补充剂及其制备方法 | |
| CN105106217A (zh) | 一种孕妇营养补充剂及其制备方法 | |
| CN101690591A (zh) | 牦牛骨髓多肽长骨增高片(粉) | |
| CN110973634A (zh) | 改善发育迟缓的营养组合物及其制备方法 | |
| CN107889889A (zh) | 一种有助于产妇恢复的雨生红球藻虾青素奶粉的配方 | |
| KR20190113685A (ko) | 저항전분 강화 쌀을 활용한 반려동물용 사료의 제조방법 | |
| CN107789444A (zh) | 一种宠物犬亮毛维生素软胶囊组方及其制备方法 | |
| Shonibare et al. | Roles of micronutrients in pregnancy | |
| CN104997020A (zh) | 一种复合乳糖酶组合物及其应用 | |
| CN117122061A (zh) | 营养组合物及其制备方法、应用和药物 | |
| Garg et al. | Nutrition 23 and Nutrients in Pregnancy | |
| CN107773575A (zh) | 一种宠物犬补钙软胶囊组方及其制备方法 | |
| CN107467673B (zh) | 一种含有三种不饱和脂肪酸和锌的复方制剂 | |
| CN105995136A (zh) | 一种供孕产妇和婴幼儿食用的喜蛋以及制备方法 | |
| CN115053928A (zh) | 一种新生儿代母乳奶粉及其制备方法 | |
| CN117598475A (zh) | 一种成人特殊医学用途全营养配方食品及其制备方法 | |
| KR20190053738A (ko) | 저항전분 강화 쌀을 활용한 반려동물용 사료의 제조방법 | |
| CN110692830A (zh) | 一种提高成活率的仔猪饲料及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |